Eczematous Drug Eruption After Ustekinumab Treatment

Pernet, C.; Guillot, B.; Bessis, Didier

doi:10.1001/archdermatol.2012.586

Cited by 17 publications

(13 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…observed a case of atopic‐like dermatitis occurring after every secukinumab injection for 6 months . EE resulting from anti‐TNF‐α treatment has been previously described . (An additional table outlining case reports or case series describing EEs during biological therapy in patients with psoriasis is available from the authors on request.)…”

Section: Clinical Features Of Patients With Eczematous Eruption (Ee)mentioning

confidence: 96%

“…In 2012, Pernet et al . reported the first case of EE occurring after the administration of ustekinumab and recently Burlando et al . observed a case of atopic‐like dermatitis occurring after every secukinumab injection for 6 months .…”

Section: Clinical Features Of Patients With Eczematous Eruption (Ee)mentioning

confidence: 98%

“…Eczematous eruption (EE) has been previously reported in 5–20% of patients with various inflammatory diseases treated with anti‐TNF‐α . Conversely, only anecdotal cases of EE induced by anti‐IL‐12/23 or anti‐IL‐17 in patients with psoriasis have been described …”

Section: Clinical Features Of Patients With Eczematous Eruption (Ee)mentioning

confidence: 99%

See 2 more Smart Citations

Eczematous eruption during anti‐interleukin 17 treatment of psoriasis: an emerging condition

et al. 2019

View full text Add to dashboard Cite

Section: Clinical Features Of Patients With Eczematous Eruption (Ee)mentioning

confidence: 96%

Section: Clinical Features Of Patients With Eczematous Eruption (Ee)mentioning

confidence: 98%

See 1 more Smart Citation

Eczematous eruption during anti‐interleukin 17 treatment of psoriasis: an emerging condition

et al. 2019

View full text Add to dashboard Cite

“…Cutaneous reactions reported with ustekinumab include pustular flares, eczematous eruptions, lymphomatoid drug reaction, erythema annulare centrifugum, and two cases of eruptive squamous cell carcinomas …”

Section: Tumor Necrosis Factor‐alphamentioning

confidence: 99%

Biologics in dermatology: adverse effects

Sehgal¹,

Pandhi

Khurana

2015

Int J Dermatology

View full text Add to dashboard Cite

Biologics are a group of drugs that precisely affect certain specific steps in the immune response and are an extremely useful group when used in an appropriate setting. However, their use can often be a double-edged sword. Careful patient selection and thorough knowledge of adverse effects is a key to their successful use in various disorders. The initial enthusiasm has gradually given way to a more cautious approach wherein a balance is sought between clinical usefulness and expected side effects. The adverse effects of the biologics most commonly used in dermatology have been carefully listed for ready reference. The plausible causes of the adverse reactions are succinctly outlined along with their incriminating factor(s). Besides, in brief, the attention has been focused on their management. The content should provide an essential didactic content for educating the practitioner.

show abstract

“…In addition, tumor necrosis factor (TNF)‐α inhibitors are known to induce a variety of cutaneous eruptions paradoxically, such as eczematous reaction, psoriasiform drug eruption, interface dermatitis and palmoplantar pustular psoriasis . Considering that UST may act partly as a TNF‐α inhibitor, this mechanism may serve as another explanation for the aggravation of AD‐like symptoms by UST …”

Section: Discussionmentioning

confidence: 99%

Exacerbation of atopic dermatitis symptoms by ustekinumab in psoriatic patients with elevated serum immunoglobulin E levels: Report of two cases

Ishiuji

Umezawa

Asahina

et al. 2018

The Journal of Dermatology

View full text Add to dashboard Cite

Psoriasis is a chronic inflammatory skin disease mainly mediated by a T-helper cell subset, Th17 cells. Recently, increased levels of total serum immunoglobulin (Ig)E have been reported in a subset of psoriatic patients. Ustekinumab (UST) is one of the most commonly used biologic agents for the treatment of moderate to severe plaque psoriasis, and a previous report also documented effectiveness of UST for psoriatic patients with high serum IgE levels. We experienced two psoriatic patients with high serum IgE levels, in whom UST completely improved psoriasis but paradoxically provoked or exacerbated atopic dermatitis (AD)-like symptoms. This reciprocal phenomenon suggests the shift of Th balance toward Th2, along with altered profiles of inflammatory cytokines. It appears prudent to consider the possibility of such adverse effects when treating psoriatic patients with UST with concomitant AD symptoms, a history of AD or high serum IgE levels.

show abstract

Eczematous Drug Eruption After Ustekinumab Treatment

Cited by 17 publications

References 5 publications

Eczematous eruption during anti‐interleukin 17 treatment of psoriasis: an emerging condition

Eczematous eruption during anti‐interleukin 17 treatment of psoriasis: an emerging condition

Biologics in dermatology: adverse effects

Exacerbation of atopic dermatitis symptoms by ustekinumab in psoriatic patients with elevated serum immunoglobulin E levels: Report of two cases

Contact Info

Product

Resources

About